PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Arzerra

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Is the prescribing physician an Oncologist or Hematologist? ☐ Yes ☐ No
Q2. What diagnosis is this drug being prescribed for? ☐ Chronic lymphocytic leukemia (CLL) ☐ Other
Q3. Please provide ICD code(s) for diagnosis
Q4. If you selected "other" in question 2, please provide documentation that use is consistent with a category 1 recommendation per NCCN compendia or guidelines.
Q5. Is the patient a NEW START to the requested medication? ☐ Yes ☐ No
Q6. What are the quantity and days supply requested?

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Arzerra

Phone: 800-728-7947 **Fax back to: 866-880-4532**

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

Q7. For previously untreated CLL, is fludarabine-based therapy is considered inappropriate for this patient?

☐ Yes ☐ No

Q8. For previously untreated CLL, will Arzerra be used in combination with chlorambucil?

☐ Yes ☐ No

Q9. For relapsed CLL, will Arzerra be given in combination with fludarabine and cyclophosphamide?

☐ Yes ☐ No

Q10. For recurrent or progressive CLL, is the patient in complete or partial response after two lines of therapy?

☐ Yes ☐ No

Q11. Has the patient previously tried and failed fludarabine and alemtuzumab?

☐ Yes ☐ No

Q12. Who is the ENTITY that will be submitting the CLAIM for the DRUG and seeking reimbursement?

☐ Pharmacy
☐ Individual prescriber
☐ Provider or specialty group
☐ Facility
☐ Other (please specify)

Q13. Provide name and NPI of the billing entity

Q14. Will the claim for the drug be submitted as a MEDICAL claim or PHARMACY claim (Note: If a pharmacy will be submitting a MEDICAL claim for drug reimbursement, answer MEDICAL)?

☐ Medical ☐ Pharmacy

Q15. Additional Comments

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Arzerra

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

Prescriber Signature

Date

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.